| Literature DB >> 11701096 |
James M Varnum1, Janina Baraniak, Renata Kaczmarek, Wojciech J Stec, Charles Brenner.
Abstract
BACKGROUND: The human FHIT gene is inactivated early in the development of many human cancers and loss of Fhit in mouse predisposes to cancer while reintroduction of FHIT suppresses tumor formation via induction of apoptosis. Fhit protein, a diadenosine polyphosphate hydrolase, does not require hydrolase activity to function in tumor suppression and may signal for apoptosis as an enzyme-substrate complex. Thus, high affinity nonhydrolyzable substrate analogs may either promote or antagonize Fhit function, depending on their features, in Fhit + cells. Previously synthesized analogs with phosphorothioadenosyl substitutions and "supercharged" branches do not bind better than natural substrates and thus have limited potential as cellular probes.Entities:
Year: 2001 PMID: 11701096 PMCID: PMC59680 DOI: 10.1186/1472-6769-1-3
Source DB: PubMed Journal: BMC Chem Biol ISSN: 1472-6769
Figure 1Structures of Fhit substrate 1 and Fhit inhibitors 6b and 12b.
Fhit inhibition by AppppA analogs varied in interadenylate linker and phosphorothiolation.
| 2600 | - | ||
| - | 2600 | ||
| - | 86000 | ||
| - | 86000 | ||
| 1500 | 220 | ||
| 4700 | 35 |
Fhit inhibition by AppppA analogs varied in phosphorothiolation and three modifications of glycerol.
| O | OH | H | 4700 | 35 | |
| O | CH3 | H | - | 76000 | |
| O | NH3 | H | - | 3000 | |
| O | H | H | - | 230 | |
| NH | H | H | - | 3300 | |
| S | H | H | - | 5200 | |
| O | -CH2-O-P-(X,O)-OAdo | -CH2-O-P-(X,O2) | 1500 | 40 | |
| O | -CH2-O-P-(X,O)-OAdo | -CH2-O-P-(X,O)-OAdo | 3200 | 65 | |
| O | -CH2O-P-(X,O2) | -CH2-O-P-(X,O2) | 900 | 700 | |
| O | -O-P-(X,O)-OAdo | H | 1500 | 78 | |
| NH | -O-P-(X,O)-OAdo | H | - | 2700 | |
| O | -O-P-(X,O2) | H | 420 | 110 | |
Physicochemical characteristics of compounds 2–17.
| 58.95; 57.64 | 752 | 24 | |
| 58.82; 57.69 | 840 | 53 | |
| 57.14; 56.92 | 812 | 50 | |
| 58.46; 58.24; 30.28 | 815 | 54 | |
| 2.3 | 750 | 35 | |
| 56.83 | 782 | 42 | |
| 115.86; 115.159 | 814 | 25 | |
| 57.64; 57.33 | 780 | 21 | |
| 59.13; 58.94 | 781 | 10 | |
| 57.32; 58.15 | 766 | 34 | |
| 60.65; 60.31 | 764 | 55 | |
| 71.85; 71.17 | 798 | 40 | |
| 56.94; 46.82 | 1267 | 20 | |
| 56.28 | 1516 | 35 | |
| 57.12; 46.71 | 1018 | 21 | |
| 57.56 | 1127 | 60 | |
| 60.17; 59.13; 58.49; 57.41 | 1125 | 15 | |
| 56.61; 45.95 | 877 | 37 |
*Compounds described in ref. [14].